alexa Medical Devices - Regulatory Intelligence - What Is It?
ISSN: 2329-6631

Journal of Developing Drugs
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd International Summit on GMP, GCP & Quality Control
September 25-26, 2014 Valencia Convention Centre, Spain

Rama K Pidaparti
Keynote: J Dev Drugs
DOI: 10.4172/2329-6631.S1.005
It is fairly well known that the Medical Devices companies need to operate in a Compliant Regulatory framework. Not just FDA, EMA et al., but also FCC and many Standards (ISO and others). Scrutiny by Regulatory Agencies? is increasing and we see lot more Warning Letters too along with the increased scrutiny. Lot of fairly established (for a long time) Medical Devices Companies has well, to sort of decent ways to manage their Regulatory Compliance. But it appears that Warning Letters received by Medical Devices companies over the past few years put them on tight schedule to get compliant in areas they are not and then require them to overhaul their entire QMS. Companies can definitely avoid getting into these situations. While the Mergers and Acquisitions can bring in disparate Quality Management Systems and lead to quality problems, often procrastination is leading to non-compliance, leading to warning letters. An effective way to manage Regulatory Compliance as well as being a better business is to have a good sustainable long-term M&A Strategy that is easy to execute for ensuring compliance. Problem could be that companies do not invest the time and money required to be compliant, while Warning Letters seem to ensure they do.
Rama Pidaparti is a Ph.D candidate from ASU and attended a Life Sciences and HealthCare courses from BEP Program at Sloan Business School, MIT. He has over 20 years of industry experience and is currently Principal Consultant, Medical Devices vertical, Wipro Technologies. He has worked at many large Global Medical Devices and Bio-Tech drug companies as a consultant, GEHC, J&J, Genzyme, Genentech, Zimmer, Medtronic, to name a few. Helping the clients with Processes and Validated implementations of Computerized Systems for R&D, Quality and Regulatory areas. He is an invited speaker on Quality and Compliance topics at similar events in the past 10 years.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version